down arrow

Enanta Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29251M1062
  • NASDAQ: ENTA
USD
11.95
-0.47 (-3.78%)

Sep 23

NAS

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
IGM Biosciences, Inc.
scPharmaceuticals, Inc.
Y-mAbs Therapeutics, Inc.
Enanta Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Vanda Pharmaceuticals, Inc.
AC Immune SA
Assertio Holdings, Inc.
Acumen Pharmaceuticals, Inc.
Lifecore Biomedical, Inc.
Inozyme Pharma, Inc.

Why is Enanta Pharmaceuticals, Inc. ?

1
Negative results in Jun 26
  • CASH AND EQV(HY) Lowest at USD 353.28 MM
  • NET SALES(Q) Lowest at USD 14.36 MM
  • INTEREST(Q) Highest at USD 4.13 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 66.67%, its profits have risen by 31.8%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Enanta Pharmaceuticals, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Enanta Pharmaceuticals, Inc.
66.67%
-0.06
108.51%
S&P 500
15.76%
1.20
13.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-8.00%
EBIT Growth (5y)
-1.95%
EBIT to Interest (avg)
-73.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.36
Sales to Capital Employed (avg)
0.24
Tax Ratio
2.51%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.79
EV to EBIT
-4.20
EV to EBITDA
-4.51
EV to Capital Employed
3.83
EV to Sales
4.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-91.16%
ROE (Latest)
-56.51%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET PROFIT(HY)

Higher at USD -32.59 MM

RAW MATERIAL COST(Y)

Fallen by 1.78% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -7.39 %

DEBTORS TURNOVER RATIO(HY)

Highest at 8.76 times

-16What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 353.28 MM

NET SALES(Q)

Lowest at USD 14.36 MM

INTEREST(Q)

Highest at USD 4.13 MM

PRE-TAX PROFIT(Q)

Lowest at USD -19.46 MM

NET PROFIT(Q)

Lowest at USD -19.5 MM

Here's what is working for Enanta Pharmaceuticals, Inc.

Debt-Equity Ratio
Lowest at -7.39 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 8.76 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by 1.78% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Enanta Pharmaceuticals, Inc.

Net Sales
At USD 14.36 MM has Fallen at -21.6%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (USD MM)

Interest
At USD 4.13 MM has Grown at 24.55%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales
Lowest at USD 14.36 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Interest
Highest at USD 4.13 MM
in the last five periods and Increased by 24.55% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit
Lowest at USD -19.46 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit
Lowest at USD -19.5 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv
Lowest at USD 353.28 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Footer loading